Design and Rationale of the Phase 3 ATTR-ACT Clinical Trial (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial)

Circulation: Heart Failure

Volumn 10, Issue 6, 2017, Pages

  Maurer, Mathew S ^a   Elliott, Perry ^b   Merlini, Giampaolo ^c   Shah, Sanjiv J ^d   Cruz, Márcia Waddington ^e   Flynn, Alison ^f   Gundapaneni, Balarama ^g   Hahn, Carolyn ^f   Riley, Steven ^f   Schwartz, Jeffrey ^f   Sultan, Marla B ^f   Rapezzi, Claudio ^h  

^a Clinical Cardiovascular Research Laboratory for the Elderly ^*  (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PAVIA   (Italy)

^d NORTHWESTERN UNIVERSITY   (United States)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f PFIZER INC   (United States)

^g SYNEOS HEALTH   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

amyloid; cardiomyopathies; double blind method; heart failure; mutation

Indexed keywords

AMYLOID; BRAIN NATRIURETIC PEPTIDE; DIFLUNISAL; PROTON PUMP INHIBITOR; TAFAMIDIS; TECHNETIUM 99M; BENZOXAZOLE DERIVATIVE;

ARTICLE; ATTR AMYLOIDOSIS; CARDIAC IMAGING; CARDIOMYOPATHY; DRUG BINDING; DRUG EFFICACY; GENOTYPE; HEART FAILURE; HOSPITALIZATION; HUMAN; MEDIAN SURVIVAL TIME; NEW YORK HEART ASSOCIATION CLASS; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCINTIGRAPHY; SIX MINUTE WALK TEST; TRANSTHYRETIN CARDIOMYOPATHY; AMYLOID NEUROPATHIES, FAMILIAL; CARDIOMYOPATHIES; DISEASE COURSE; DISEASE MANAGEMENT; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL (TOPIC); PROCEDURES;

ADMINISTRATION, ORAL; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; CARDIOMYOPATHIES; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MANAGEMENT; DISEASE PROGRESSION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85021084170     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003815     Document Type: Article

References (53)

1. Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A. Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol. 2010;7:398-408. doi: 10. 1038/nrcardio. 2010. 67.
2. Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J. 2012;164:222-228. e1. doi: 10. 1016/j. ahj. 2012. 04. 015.
3. Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC. Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation. 2016;133:282-290. doi: 10. 1161/ circulationaha. 115. 018852.
4. Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A. Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol. 2016;68:1014-1020. doi: 10. 1016/j. jacc. 2016. 06. 033.
5. Pinney JH, Whelan CJ, Petrie A, Dungu J, Banypersad SM, Sattianayagam P, Wechalekar A, Gibbs SD, Venner CP, Wassef N, McCarthy CA, Gilbertson JA, Rowczenio D, Hawkins PN, Gillmore JD, Lachmann HJ. Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc. 2013;2:e000098. doi: 10. 1161/ jaha. 113. 000098.
6. Blake CC, Geisow MJ, Oatley SJ, Rérat B, Rérat C. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1. 8 A. J Mol Biol. 1978;121:339-356.
7. Monaco HL, Rizzi M, Coda A. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. Science. 1995;268:1039-1041.
8. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol. 2012;421:185-203. doi: 10. 1016/j. jmb. 2011. 12. 060.
9. Quintas A, Vaz DC, Cardoso I, Saraiva MJ, Brito RM. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants. J Biol Chem. 2001;276:27207-27213. doi: 10. 1074/jbc. M101024200.
10. Saraiva MJ. Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum Mutat. 2001;17:493-503. doi: 10. 1002/humu. 1132.
11. Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Planté-Bordeneuve V, Rapezzi C, Said G, Salvi F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis. 2013;8:31. doi: 10. 1186/1750-1172-8-31.
12. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015;86:1036-1043. doi: 10. 1136/jnnp-2014-308724.
13. Adams D, Coelho T, Obici L, Merlini G, Mincheva Z, Suanprasert N, Bettencourt BR, Gollob JA, Gandhi PJ, Litchy WJ, Dyck PJ. Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study. Neurology. 2015;85:675-682. doi: 10. 1212/ wnl. 0000000000001870.
14. Coelho T, Maurer MS, Suhr OB. THAOS-The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29:63-76. doi: 10. 1185/03007995. 2012. 754348.
15. Mariani LL, Lozeron P, Théaudin M, Mincheva Z, Signate A, Ducot B, Algalarrondo V, Denier C, Adam C, Nicolas G, Samuel D, Slama MS, Lacroix C, Misrahi M, Adams D; French Familial Amyloid Polyneuropathies Network (CORNAMYL) Study Group. Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol. 2015;78:901-916. doi: 10. 1002/ana. 24519.
16. Connors LH, Lim A, Prokaeva T, Roskens VA, Costello CE. Tabulation of human transthyretin (TTR) variants, 2003. Amyloid. 2003;10:160-184. doi: 10. 3109/13506120308998998.
17. Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36:411-423. doi: 10. 1002/ mus. 20821.
18. Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar AD. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat. 2014;35:E2403-E2412. doi: 10. 1002/humu. 22619.
19. Jacobson DR, Alexander AA, Tagoe C, Buxbaum JN. Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14, 333 African-Americans. Amyloid. 2015;22:171-174. doi: 10. 3109/13506129. 2015. 1051219.
20. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;387:2641-2654. doi: 10. 1016/s0140-6736(15)01274-x.
21. Dharmarajan K, Maurer MS. Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc. 2012;60:765-774. doi: 10. 1111/j. 1532-5415. 2011. 03868. x.
22. Bennani Smires Y, Victor G, Ribes D, Berry M, Cognet T, Mejean S, Huart A, Roussel M, Petermann A, Roncalli J, Carrie D, Rousseau H, Berry I, Chauveau D, Galinier M, Lairez O. Pilot study for left ventricular imaging phenotype of patients over 65 years old with heart failure and preserved ejection fraction: the high prevalence of amyloid cardiomyopathy. Int J Cardiovasc Imaging. 2016;32:1403-1413. doi: 10. 1007/ s10554-016-0915-z.
23. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36:2585-2594. doi: 10. 1093/eurheartj/ehv338.
24. Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286-1300. doi: 10. 1161/circulationaha. 111. 078915.
25. Connors LH, Prokaeva T, Lim A, Théberge R, Falk RH, Doros G, Berg A, Costello CE, O'Hara C, Seldin DC, Skinner M. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J. 2009;158:607-614. doi: 10. 1016/j. ahj. 2009. 08. 006.
26. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Planté-Bordeneuve V, Schmidt HH, Merlini G. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 2015;66:2451-2466. doi: 10. 1016/j. jacc. 2015. 09. 075.
27. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133:2404-2412. doi: 10. 1161/ CIRCULATIONAHA. 116. 021612.
28. Bokhari S, Castaño A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging. 2013;6:195-201. doi: 10. 1161/circimaging. 112. 000132.
29. Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol. 2016;1:880-889. doi: 10. 1001/jamacardio. 2016. 2839.
30. Haq M, Pawar S, Berk JL, Miller EJ, Ruberg FL. Can 99m-Tc-Pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? [published online ahead of print August 20, 2016]. JACC Cardiovasc Imaging. doi: 10. 1016/j. jcmg. 2016. 06. 003.
31. Connors LH, Doros G, Sam F, Badiee A, Seldin DC and Skinner M. Clinical features and survival in senile systemic amyloidosis: comparison to familial transthyretin cardiomyopathy. Amyloid. 2011;18(suppl 1):157-159. doi: 10. 3109/13506129. 2011. 574354059.
32. Givens RC, Russo C, Green P, Maurer MS. Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center. Aging Health. 2013;9:229-235. doi: 10. 2217/ahe. 13. 10.
33. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, Wallin BG, Seymour A, Richardson S, Hawkins PN, Pepys MB. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet. 1993;341:1113-1116.
34. Lewis WD, Skinner M, Simms RW, Jones LA, Cohen AS, Jenkins RL. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplant. 1994;8(2 pt 1):107-110.
35. Liepnieks JJ, Benson MD. Progression of cardiac amyloid deposition in hereditary transthyretin amyloidosis patients after liver transplantation. Amyloid. 2007;14:277-282. doi: 10. 1080/13506120701614032.
36. Tojo K, Sekijima Y, Kelly JW, Ikeda S. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neurosci Res. 2006;56:441-449. doi: 10. 1016/j. neures. 2006. 08. 014.
37. Berk JL, Suhr OB, Obici L, Sekijima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD, Litchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda S, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck PJ; Diflunisal Trial Consortium. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA. 2013;310:2658-2667. doi: 10. 1001/jama. 2013. 283815.
38. Castano A, Helmke S, Alvarez J, Delisle S, Maurer MS. Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail. 2012;18:315-319. doi: 10. 1111/j. 1751-7133. 2012. 00303. x.
39. Bulawa CE, Connelly S, Devit M, Wang L, Weigel C, Fleming JA, Packman J, Powers ET, Wiseman RL, Foss TR, Wilson IA, Kelly JW, Labaudiniere R. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA. 2012;109:9629-9634. doi: 10. 1073/pnas. 1121005109.
40. Razavi H, Palaninathan SK, Powers ET, Wiseman RL, Purkey HE, Mohamedmohaideen NN, Deechongkit S, Chiang KP, Dendle MT, Sacchettini JC, Kelly JW. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew Chem Int Ed Eng. 2003;42:2758-2761. doi: 10. 1002/anie. 200351179.
41. Maurer MS, Grogan DR, Judge DP, Mundayat R, Packman J, Lombardo I, Quyyumi AA, Aarts J, Falk RH. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. Circ Heart Fail. 2015;8:519-526. doi: 10. 1161/ circheartfailure. 113. 000890.
42. Merlini G, Planté-Bordeneuve V, Judge DP, Schmidt H, Obici L, Perlini S, Packman J, Tripp T, Grogan DR. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis. J Cardiovasc Transl Res. 2013;6:1011-1020. doi: 10. 1007/s12265-013-9512-x.
43. Ando Y, Sekijima Y, Obayashi K, Yamashita T, Ueda M, Misumi Y, Morita H, Machii K, Ohta M, Takata A, Ikeda S. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study. J Neurol Sci. 2016;362:266-271. doi: 10. 1016/j. jns. 2016. 01. 046.
44. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Suhr OB, Conceicao I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol. 2013;260:2802-2814. doi: 10. 1007/s00415-013-7051-7.
45. Coelho T, Maia LF, Martins da Silva A, Waddington Cruz M, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Wilson A, Grogan DR. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology. 2012;79:785-792. doi: 10. 1212/WNL. 0b013e3182661eb1.
46. Damy T, Judge DP, Kristen AV, Berthet K, Li H, Aarts J. Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis. J Cardiovasc Transl Res. 2015;8:117-127. doi: 10. 1007/ s12265-015-9613-9.
47. Rappley I, Monteiro C, Novais M, Baranczak A, Solis G, Wiseman RL, Helmke S, Maurer MS, Coelho T, Powers ET, Kelly JW. Quantification of transthyretin kinetic stability in human plasma using subunit exchange. Biochemistry. 2014;53:1993-2006. doi: 10. 1021/bi500171j.
48. Cho Y, Baranczak A, Helmke S, Teruya S, Horn EM, Maurer MS, Kelly JW. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy). Amyloid. 2015;22:175-180. doi: 10. 3109/13506129. 2015. 1063485.
49. Coelho T, Merlini G, Bulawa CE, Fleming JA, Judge DP, Kelly JW, Maurer MS, Planté-Bordeneuve V, Labaudiniere R, Mundayat R, Riley S, Lombardo I, Huertas P. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol Ther. 2016;5:1-25. doi: 10. 1007/s40120-016-0040-x.
50. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999;18:1341-1354.
51. Samman Tahhan A, Vaduganathan M, Kelkar A, Georgiopoulou VV, Kalogeropoulos AP, Greene SJ, Fonarow GC, Gheorghiade M, Butler J. Trends in heart failure clinical trials from 2001-2012. J Card Fail. 2016;22:171-179. doi: 10. 1016/j. cardfail. 2015. 06. 014.
52. Butler J, Tahhan AS, Georgiopoulou VV, Kelkar A, Lee M, Khan B, Peterson E, Fonarow GC, Kalogeropoulos AP, Gheorghiade M. Trends in characteristics of cardiovascular clinical trials 2001-2012. Am Heart J. 2015;170:263-272. doi: 10. 1016/j. ahj. 2015. 05. 006.
53. U. S. Food and Drug Administration. Rare Diseases: Common Issues in Drug Development. 2015. http://www. fda. gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm423881. htm. Accessed April 5, 2017.